CG Oncology, Inc. Common stock CGON NASDAQ

CG Oncology Inc is a clinical biopharmaceutical company developing innovative therapies for bladder cancer treatment. The company's lead product candidate, cretostimogene, is designed as a bladder-sparing therapeutic in clinical development for high-risk non-muscle invasive bladder cancer patients who have failed to respond to BCG immunotherapy, the current standard treatment. CG Oncology aims to address a significant unmet medical need in oncology by offering an alternative treatment option for BCG-unresponsive patients and positioning cretostimogene as a potential backbone therapy for bladder cancer management.